ArticleBiomolecules2026
TF-GateNet: An Interpretable and Biologically Guided Framework for Primary-Metastatic State Prediction from Somatic Genomic Alterations.
Article in Biomolecules, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
Metastasis remains a major cause of cancer mortality, making reliable primary-metastatic state prediction from somatic genomic alterations clinically important yet technically difficult. We present TF-GateNet, a biologically constrained neural network that combines TF-aware feature integration based on TRRUST and DoRothEA TF-gene regulatory priors with sample-specific dynamic gating on a Reactome-defined hierarchical sparse backbone. The model was evaluated on multi-center prostate and breast-cancer cohorts using mutation and copy-number features across 10 repeated runs on a fixed 80/10/10 split, together with independent prostate external validation, and was compared with biologically informed neural-network baselines (P-NET, BKGNet-Pathway, and BKGNet-Protein), a dense feed-forward neural network (FNN), and conventional machine-learning baselines (LR, SVM, RF, DT, and XGBoost). On prostate, TF-GateNet achieved the best internal performance (AUROC 0.954 ± 0.005; AUPRC 0.925 ± 0.007) and the best combined external performance (AUROC 0.952 ± 0.009; AUPRC 0.898 ± 0.018). On breast, TF-GateNet achieved the strongest internal ranking performance, reaching AUROC 0.893 ± 0.004 and AUPRC 0.835 ± 0.006. Ablation analysis indicated that TF-aware integration accounted for the larger prostate gain, whereas within the TF-GateNet family on breast, both TF-aware integration and dynamic gating contributed positively. Interpretability analysis further supported a cross-level route from TF-related genomic perturbation cues to genes, pathways, and phenotype-associated predictions. These results position TF-GateNet as a biologically grounded and interpretable framework for primary-metastatic state prediction, with the strongest overall evidence in prostate cancer and favorable internal evidence in breast cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.